As filed with the Securities and Exchange Commission on November 9, 2017

Registration No. 333-             

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 


 

ARALEZ PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 


 

British Columbia, Canada

 

98-1283375

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

7100 West Credit Avenue, Suite 101

Mississauga, Ontario, Canada, L5N 0E4

(Address of Principal Executive Offices)

 

Aralez Pharmaceuticals Inc.

Amended and Restated 2016 Long-Term Incentive Plan

(Full title of the plan)

 


 

Adrian Adams

Chief Executive Officer

Aralez Pharmaceuticals Inc.

7100 West Credit Avenue, Suite 101

Mississauga, Ontario L5N 0E4

(905) 876-1118

(Name, address and telephone number of agent for service)

 


 

With copies to:

 

Adam M. Turteltaub, Esq.

 

Eric L. Trachtenberg

Russell L. Leaf, Esq.

 

General Counsel

Willkie Farr & Gallagher LLP

 

Aralez Pharmaceuticals Inc.

787 Seventh Avenue

 

7100 West Credit Avenue, Suite 101

New York, New York 10019

 

Mississauga, Ontario L5N 0E4

(212) 728-8000

 

(905) 876-1118

 


 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

o

 

 

Accelerated filer

x

 

 

 

 

 

 

Non-accelerated filer

o

(Do not check if a smaller reporting company)

 

Smaller reporting company

o

 

 

 

 

 

 

 

 

 

 

Emerging growth company

o

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

o

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of each class of
securities to be registered

 

Amount
to be
registered(1)

 

Proposed
maximum
offering price
per share(2)

 

Proposed
maximum
aggregate
offering price(2)

 

Amount of
registration fee

 

Common shares, without par value

 

4,300,000

 

$

1.95

 

$

8,385,000

 

$

1,043.94

 

 

(1) This Registration Statement on Form S-8 (this “Registration Statement”) covers 4,300,000 additional common shares, no par value per share (“Common Shares”), of Aralez Pharmaceuticals Inc. (the “Company” or the “Registrant”) which may be issued under the Aralez Pharmaceuticals Inc. Amended and Restated 2016 Long-Term Incentive Plan (the “Plan”).  In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminate number of additional Common Shares which may be offered and issued pursuant to the Plan to prevent dilution resulting from adjustments as a result of stock dividends, stock splits, reverse stock splits, recapitalizations, reclassifications, mergers, split-ups, reorganizations, consolidations and other capital adjustments.

 

(2)  Pursuant to Rule 457(c) and 457(h) of the Securities Act, the proposed maximum offering price per share and the proposed maximum aggregate offering are estimated solely for the purpose of calculating the amount of the registration fee and are based on the average of the high and low prices of the Registrant’s Common Shares as reported on the NASDAQ Stock Market LLC on November 3, 2017. Pursuant to Rule 457(h)(2) under the Securities Act, no separate fee is required to register plan interests.

 

 

 



 

EXPLANATORY NOTE

 

On May 3, 2017, the stockholders of Aralez Pharmaceuticals Inc. (the “Registrant”) approved the Aralez Pharmaceuticals Inc. Amended and Restated 2016 Long-Term Incentive Plan (the “Plan”) that increased the share authorization by 4,300,000 common shares, no par value per share.  The shares registered on this Registration Statement are in addition to the (i) 5,262,577 common shares registered on Form S-8 on February 8, 2016 (Registration No. 333-209433) and (ii) 1,018,639 common shares registered on Form S-8 on March 15, 2016 (333-210206) (collectively, the “Prior Registration Statements”).  This Registration Statement relates to the same class of securities and the same employee benefit plan to which the Prior Registration Statements relates and, in accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.

 

EXHIBIT INDEX

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed

No.

 

Description

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

Herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

5.1

 

Opinion of Stikeman Elliott LLP

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of Ernst & Young LLP, independent registered public accounting firm

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.2

 

Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.3

 

Consent of KPMG LLP, independent auditors

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.4

 

Consent of UHY McGovern Hurley LLP, independent auditors for Tribute Pharmaceuticals Canada Inc.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.5

 

Consent of Stikeman Elliott LLP (included in Exhibit 5.1)

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

Power of Attorney (included on signature page of this Registration Statement)

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

99.1

 

Aralez Pharmaceuticals Inc. Amended and Restated 2016 Long-Term Incentive Plan

 

DEF 14A

 

001-37691

 

A

 

March 23, 2017

 

 

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Toronto, Province of Ontario, Canada, on this 9th day of November, 2017.

 

 

Aralez Pharmaceuticals Inc.

 

 

 

 

 

 

 

By:

/s/ Adrian Adams

 

 

Name: Adrian Adams

 

 

Title: Chief Executive Officer

 

3



 

POWER OF ATTORNEY AND SIGNATURES

 

We, the undersigned officers and directors of Aralez Pharmaceuticals Inc., hereby severally constitute and appoint each of Adrian Adams and Eric L. Trachtenberg, our true and lawful attorneys-in-fact, with full power to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Registration Statement on Form S-8, and to file the same, with any exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and grant such attorneys-in-fact full power and authority to do all such things in our names and on our behalf in our capacities as officers and directors to enable Aralez Pharmaceuticals Inc. to comply with the provisions of the Securities Act, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to any and all amendments to this Registration Statement.

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Adrian Adams

 

Chief Executive Officer

 

November 9, 2017

Adrian Adams

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Scott Charles

 

Chief Financial Officer

 

November 9, 2017

Scott Charles

 

(Principal Financial Officer, Principal Accounting Officer)

 

 

 

 

 

 

 

/s/ Neal F. Fowler

 

Director

 

November 9, 2017

Neal F. Fowler

 

 

 

 

 

 

 

 

 

/s/ Arthur S. Kirsch

 

Director

 

November 9, 2017

Arthur S. Kirsch

 

 

 

 

 

 

 

 

 

/s/ Kenneth B. Lee, Jr.

 

Director

 

November 9, 2017

Kenneth B. Lee, Jr.

 

 

 

 

 

 

 

 

 

/s/ Seth A. Rudnick, M.D.

 

Director

 

November 9, 2017

Seth A. Rudnick, M.D.

 

 

 

 

 

 

 

 

 

/s/ Rob Harris

 

Director

 

November 9, 2017

Rob Harris

 

 

 

 

 

 

 

 

 

/s/ F. Martin Thrasher

 

Director

 

November 9, 2017

F. Martin Thrasher

 

 

 

 

 

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

 

Pursuant to the requirements of the Securities Act, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this Registration Statement on November 9, 2017.

 

 

AUTHORIZED U.S. REPRESENTATIVE

 

 

 

 

By:

/s/ Eric Trachtenberg

 

Eric Trachtenberg

 

Secretary

 

Aralez Pharmaceuticals US Inc.

 

4